Abstract

BackgroundPersistent infection with high-risk human papillomavirus (hrHPV) is a critical step in cervical carcinogenesis. We report on type-specific hrHPV persistence, clearance and incidence among screen-positive Rwandan women living with HIV (WLWH).MethodsThis was a nested analysis from a large cervical cancer screening study of ~ 5000 Rwandan WLWH. Women who tested positive for hrHPV and/or visual inspection with acetic acid were referred to colposcopy. For a subset of women (n = 298) who were ≥ 6 months delayed in receiving colposcopy, we tested their screening and colposcopy visit specimens using the AmpFire HPV genotyping assay that tests 14 hrHPV types (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68) individually.ResultsThe mean, median (interquartile range [IQR]) and range of time between the screening and colposcopy visits were 644, 650 (490–820.5) and 197–1161 days, respectively. Mean, median (IQR) and range of age at the screening visit were 38, 37 (34–43) and 30–54 years, respectively. Two-hundred eighty-three (95.0%) had CD4 count (cells per mm3) data available at baseline with mean, median (IQR) and range of 592, 513 (346–717) and 0–7290, respectively. Two-hundred thirty-five WLWH were positive for at least one hrHPV type at the screening visit, of whom 50.2% had at least one HPV type-specific infection persist; 37.2% of all HPV infections detected at the screening visit persisted. Compared to all other HPV types in aggregate, HPV16 (vs. non-HPV16 types) (47.7%, p = 0.03) and HPV33 (vs. non-HPV33 types) (56.7%, p = 0.03) were significantly more likely, and HPV39 (vs. non-HPV39 types) (6.7%, p = 0.01), HPV51 (vs. non-HPV51 types) (15.6%, p < 0.01), and HPV66 (vs. non-HPV66 types (17.9%, p = 0.04) were significantly less likely, to persist. Lower CD4 counts were associated with having any persistent hrHPV infection (ptrend = 0.04) and multiple persistent hrHPV infections (ptrend = 0.04).ConclusionThere is a significant proportion of WLWH with persistent hrHPV infection, emphasizing the need to vaccinate them against HPV prior to becoming sexually active.

Highlights

  • Cervical cancer is the fourth most common cancer among women and the fourth leading cause of female cancer deaths worldwide with 570,000 new cases and 311,000 deaths occurring in 2018 [1]

  • Women living with human immunodeficiency virus (HIV) (WLWH) bear an even greater burden of cervical cancer compared to their HIV-negative counterparts [3,4,5] and cervical cancer was included as an acquired immunodeficiency syndrome (AIDS) defining illness in 1993 [6]

  • Their screening- and colposcopy-visit specimens were tested for high-risk human papillomavirus (hrHPV) using both the Xpert Human Papillomavirus (HPV) test and the AmpFire HPV genotyping assay, which tests for 15 HPV types, including 14 hrHPV types (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68) that are detected by the Xpert assay

Read more

Summary

Introduction

Cervical cancer is the fourth most common cancer among women and the fourth leading cause of female cancer deaths worldwide with 570,000 new cases and 311,000 deaths occurring in 2018 [1]. Especially Sub-Saharan Africa (SSA), bears the greatest burden of cervical cancer with incidence and mortality rates in Southern, Eastern and Western Africa 7–10 times those in North America, Australia/New Zealand and Western Asia [1]. This high burden of cervical cancer is in part due to the high prevalence of human immunodeficiency virus (HIV) infection and acquired immunodeficiency syndrome (AIDS). Infection with high-risk human papillomavirus (hrHPV), the necessary cause of virtually all cervical cancer, is a very common sexually transmitted infection [7]. We report on type-specific hrHPV persistence, clearance and incidence among screen-positive Rwandan women living with HIV (WLWH)

Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call